tiprankstipranks
Trending News
More News >
Kineta, Inc. (KANT)
OTHER OTC:KANT
Advertisement

Kineta (KANT) Price & Analysis

Compare
697 Followers

KANT Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

19.85%<0.01%3.04%100.00%
19.85% Insiders
3.04% Other Institutional Investors
100.00% Public Companies and
Individual Investors

KANT FAQ

What was Kineta, Inc.’s price range in the past 12 months?
Kineta, Inc. lowest stock price was $0.18 and its highest was $1.15 in the past 12 months.
    What is Kineta, Inc.’s market cap?
    Kineta, Inc.’s market cap is $4.55M.
      When is Kineta, Inc.’s upcoming earnings report date?
      Kineta, Inc.’s upcoming earnings report date is May 08, 2025 which is 80 days ago.
        How were Kineta, Inc.’s earnings last quarter?
        Currently, no data Available
        Is Kineta, Inc. overvalued?
        According to Wall Street analysts Kineta, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Kineta, Inc. pay dividends?
          Kineta, Inc. pays a Notavailable dividend of $1.429 which represents an annual dividend yield of N/A. See more information on Kineta, Inc. dividends here
            What is Kineta, Inc.’s EPS estimate?
            Kineta, Inc.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Kineta, Inc. have?
            Kineta, Inc. has 51,099,000 shares outstanding.
              What happened to Kineta, Inc.’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Kineta, Inc.?
              Currently, no hedge funds are holding shares in KANT

              Company Description

              Kineta, Inc.

              Kineta, Inc. (KANT) is a clinical-stage biotechnology company focused on developing novel therapies in the immuno-oncology sector. The company's core products include innovative treatments aimed at enhancing the immune system's ability to combat cancer. Utilizing advanced immunotherapeutic approaches, Kineta seeks to address critical unmet needs in oncology, offering potential breakthroughs in cancer treatment.
              Similar Stocks
              Company
              Price & Change
              Follow
              Cyclacel Pharmaceuticals
              Brainstorm Cell Therapeutics
              ESSA Pharma
              Kura Oncology
              BioVie
              Galera Therapeutics
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis